BET-BAY 002 is primarily utilized in the field of medicinal chemistry and drug discovery, particularly in the development of inhibitors targeting bromodomain-containing proteins. These proteins play a critical role in regulating gene expression by recognizing acetylated lysine residues on histone proteins. By inhibiting these bromodomains, BET-BAY 002 can modulate transcriptional pathways, making it a valuable tool in researching and treating diseases such as cancer, inflammation, and other conditions driven by aberrant gene expression. Its application extends to preclinical studies where it helps in understanding the biological mechanisms of bromodomain proteins and evaluating the therapeutic potential of bromodomain inhibitors.